Drug intelligence / Profile preview

1-13 carbon leucine + deuterated water

Development stage
Unknown
Lead developer
Università di Padova
Modality
Small Molecules
Administration
Intravenous
01

Overview

1-13 carbon leucine + deuterated water is a research tracer combination consisting of 1-13C leucine (carbon-13 labeled leucine) and deuterated water (2H2O, deuterium oxide). Developed for use in clinical studies by the University of Padova, this combination serves as a stable isotope tracer system to investigate lung surfactant metabolism and fluid dynamics in patients with Acute Respiratory Distress Syndrome (ARDS) and Acute Lung Injury (ALI). 1-13C leucine acts as a metabolic precursor to measure the fractional synthesis rate and turnover of surfactant protein-B (SP-B), while deuterated water serves as a precursor for disaturated-phosphatidylcholine (DSPC)-palmitate and allows for the calculation of total body water and water turnover. This non-radioactive approach provides critical insights into the pathophysiology of surfactant deficiency or dysfunction in critically ill patients without the risks associated with radioactive isotopes.

Other names
1-13C leucine + 2H2O1-13C leucine + deuterated waterCarbon-13 labeled leucine and deuterium oxideCarbon13 labeled leucine and deuterium oxideCarbon 13 labeled leucine and deuterium oxide
02

Targets

SFTPB (Pulmonary surfactant protein B)

Beyond the preview

Go deeper on 1-13 carbon leucine + deuterated water.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on 1-13 carbon leucine + deuterated water.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call